#1
|
||||
|
||||
Íîâàÿ ìóòàöèÿ â CALR â äèàãíîñòèêå è ïðîãíîçå òðîìáîöèòåìèè.
Íîâàÿ ìóòàöèÿ â ãåíå êàëðåòèêóëèíà CALR ex.9 ïîìîãàåò óñòàíîâëåíèþ äèàãíîçà ýññåíöèàëüíàÿ òðîìáîöèòåìèÿ (îáíàðóæèâàåòñÿ ó êàæäîãî 4-ãî ñ äàííûì äèàãíîçîì èëè ó áîëüøèíñòâà (>70%) ïàöèåíòîâ ñ îòñóòñòâèåì ìóòàöèé â JaK-2), ïîäðîáíåå:
JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |